Back to today’s briefing

Story perspectives

Liraglutide Cuts Migraine Days in Obese Patients

7/5/2025

28 5

Summary

Story summary

A groundbreaking pilot trial at the University of Naples revealed that liraglutide, a GLP-1 agonist, slashed migraine days from 19.8 to 10.7 for patients battling obesity. This promising discovery hints at liraglutide's potential as a standalone treatment for chronic migraines, urging further investigation into its underlying mechanisms and efficacy.

1 of 1

Story summary

A groundbreaking pilot trial at the University of Naples revealed that liraglutide, a GLP-1 agonist, slashed migraine days from 19.8 to 10.7 for patients battling obesity. This promising discovery hints at liraglutide's potential as a standalone treatment for chronic migraines, urging further investigation into its underlying mechanisms and efficacy.